Alkem Laboratories (Alkem) is a leading Indian-origin global pharmaceutical company with expertise across generics, specialty pharmaceuticals, biosimilars, and medical devices. The company is a trusted healthcare provider across both acute and chronic therapy segments.

Innovation remains central to Alkem’s growth strategy. The company has pioneered several technologically advanced and cost-effective pharmaceutical solutions across its integrated value chain, from product development and manufacturing to distribution. Alkem operates across multiple countries and has built an extensive commercial infrastructure.

Alkem’s strong brand equity is underpinned by an experienced management team, robust manufacturing capabilities, an unwavering commitment to quality, and a culture rooted in integrity and resilience. The company is actively investing in several high-growth platforms, including injectables and biosimilars, as well as emerging technology platforms such as mRNA, viral vectors, and antibody-drug conjugates (ADCs).

In India, Alkem holds leadership positions in several acute therapy areas, including anti-infectives, gastrointestinal, pain management, and vitamins, minerals, and nutrients (VMN). The company has maintained its leadership in the anti-infective segment for many years and is also a major player in the trade generics market.

Business area of the company

The company is a leading Indian pharmaceutical company that provides high-quality medicines to patients. It is one of the largest pharmaceutical companies in India, with a strong presence in key therapeutic areas, including anti-infectives, gastrointestinal disorders, pain management, and nutritional supplements.

Offerings of the company

Therapies

• Anti - Infective
• Anti-Osteoporosis
• Cardiology
• Neurology
• Dermatology
• Diabetology
• Gastroenterology
• Gynaecology
• Oncology
• Ophthalmology
• Respiratory
• Rheumatology
• Urology

Rx Products: The company has a wide range of products spanning multiple Therapeutic Areas (TA) such as Anti-infective, Gastroenterology, Pain Relief/Analgesic, Anti-diabetic, Cardiology, Dermatology, Neurology/Central Nervous System (CNS), and Vitamins, Minerals, and Nutrition.

Alkem Wellness: Alkem Wellness brings Alkem Laboratories' trusted legacy to the trade generics segment, ensuring quality medicines reach every corner of India. With a strong portfolio across key therapies and a nationwide distribution network, it makes dependable healthcare accessible and within reach for all.

Awards and Recognition

2016:

• Won the 'HR Tech Award for Best use of Technology in Human Resources' by World HRD Congress.
• Won the Best Demand Planning and Forecasting Company - Pharmaceutical by ISCM's - SCMPro's in Demand Planning and Forecasting Forum Awards 2016.
• Alkem-Pentacare division won the most enterprising company in leveraging technology in use of Mobile Applications by DigiPharmaX.
• Brand 'Pan' received ‘Brand of the Year' award in sub-chronic category at AWACS Awards, 2016.
• Alkem won the Guinness World Record for creating largest Blister Pack Mosiac at RSSDI Hyderabad.

2017:

• Alkem Corporate Video won the 1st runners up award in the Best Corporate Film for driving Employee Engagement initiatives in the Mega Corporate Film Festival and Awards held in Mumbai.
• Received the Best Stand-out IR award 2017 by IR Society India in association with KPMG and Bloomberg.
• Won the People Matters league Awards - Learning & Development 2017 - Best in Cultural Transformation in Mumbai.
• Won the Guinness world Records for creating largest Bindi Mosiac at RSSDI Bhubaneswar.
• Won the Rising Digital Star of the Year for various digital initiatives by DigiPharmaX Awards 2017.

2018:

• Best Innovative CSR Project at CSR Summit & Awards 2018.
• Brand ‘Clavam’ received Brand of the Year 2018 Award at AWACS Awards for marketing excellence.
• Business Excellence Award 2018 for Best Range of ICU Products, Pharma and Health Care Summit organized by CIMS (Current Index of Medical Specialties).

2019:

• Express Pharma Excellence Award at Pharma CXO Summit 2011.
• Best Use of Technology in Sales Hiring by Global Eminence Digital Awards sponsored by AQUILAA.

2020:

• CIO Conclave and Awards 2020 in the category ‘Best IT Team of the year’.
• Alkem Laboratories as Great Place to Work-Certified organization in the large organization category across industries.
• India's Best Workplaces in Biotechnology & Pharmaceuticals.

2023

• Indian Family Business Awards 2023 - Winner in the Most Innovative, Disruptive & Transformational category (GIGA Jury Select).
• Best CSR Performer 2022–23 - Recognised at the 2nd North East CSR Forum (NECSRF) for impactful work in Sikkim.

2024

• IMAGEXX Silver 2024 For the “50 Years of Excellence” corporate branding campaign by Adgully.
• Gartner Eye on Innovation 2024 - Recognised at the 16th Express Logistics & Supply Chain Leadership Conclave.
• India’s Best Workplaces 2024 - Featured by Great Place to Work in Pharma, Healthcare & Biotech.

2025

• WOW Workplace Award 2025 - Recognised in the Pharmaceutical & Healthcare category for fostering a vibrant, inclusive workplace, based entirely on employee feedback.
• Best CSR Healthcare Project 2025 - Awarded at the Bharat CSR & Sustainability Awards for its Cancer Care initiative in Bihar.

Milestones

• 1973: Inception of Alkem Laboratories.
• 1978: First manufacturing unit was established at Taloja near Mumbai.
• 1992: Second manufacturing facility established at Mandva, Gujarat which was converted into an API facility in 2005.
• 2003: First research and development facility established at Taloja.
• 2006: Taxim became India’s first anti-infective drug to surpass annual sales figure of ` 1,000 million in the domestic market.
• 2007: Filed the first ANDA in the United States for the drug Amlodipine.
• 2009: Received the first ANDA approval in the United States for the drug Amlodipine.
• 2009: Acquired Pharmacor Pty. Ltd., a generic pharmaceutical company in Australia.
• 2010: Acquired Ascend Laboratories, pharmaceutical company in the United States.
• 2011: Acquired Enzene, a company engaged in the development of biosimilars in India.
• 2012: Acquired an API manufacturing facility in the United States.
• 2014: Acquired the ‘Clindac-A’ brand in India from Galderma S.A.
• 2014: Clavam surpassed Rs 2,000 million domestic sales figure.
• 2015: Acquired a formulation manufacturing facility in the United States.
• 2015: Successfully completed Initial Public Offering (IPO).
• 2018: Revenue from the US market crossed $200 million in annual sales.
• 2019: Crossed the revenue milestone of $1 billion.
  
• 2020: New manufacturing facilities launched Pune (biologics/biosimilars).
• 2021: First biosimilar launched from Enzene in India; Pulmocare division debuts in respiratory therapy.
• 2022: Alkem named “Pharma Company of the Year” at ET Pharma World Awards; Clavam crosses Rs 6 billion in sales.
• 202324: 50 years of Alkem; Launched Eyecare, ophthalmology division
• 2024-25: Strategic acceleration: Inclusion in the MSCI India Index 
• 2024-25: Adroit acquisition
• 2024-25: Entry into Medtech segment via licensing agreement with Exactech and acquistion of Bombay Ortho.